hVIVO (LON:HVO) Shares Up 7.1% - Here's Why

hVIVO plc (LON:HVO - Get Free Report)'s share price rose 7.1% on Thursday . The company traded as high as GBX 13.50 ($0.17) and last traded at GBX 13.50 ($0.17). Approximately 1,485,919 shares changed hands during trading, a decline of 55% from the average daily volume of 3,282,514 shares. The stock had previously closed at GBX 12.60 ($0.16).

hVIVO Stock Performance

The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The stock has a fifty day moving average price of GBX 16.63 and a 200-day moving average price of GBX 21.29. The firm has a market cap of £104.72 million, a price-to-earnings ratio of 6.10 and a beta of 0.97.

Insider Buying and Selling at hVIVO

In other news, insider Yamin Mo' Khan sold 3,062,246 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.22), for a total value of £520,581.82 ($662,655.07). 14.03% of the stock is currently owned by corporate insiders.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.